" class="no-js "lang="en-US"> Ken Takeshita - Medtech Alert
Thursday, March 30, 2023

Breaking News

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Implantica Launches RefluxStop™ in Italy Granular Therapeutics to Accelerate Development of Next-Generation Pipeline for Treating Mast Cell Driven Diseases Xeris Biopharma Appoints Ricki Fairley to Board of Directors AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson’s Disease New Imaging Method for Evaluating Transport of Oxygen to Blood Cells
Ken Takeshita

Ken Takeshita

About Ken Takeshita

Related Story

Diseases

 Enhertu Granted Breakthrough Therapy Designation in US for Patients with HER2-positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-based Regimens | Pharmtech Focus

Enhertu Granted Breakthrough Therapy Designation in US for Patients with HER2-positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-based Regimens

October 4 2021

The Food and Drug Administration (FDA) has granted Enhertu (trastuzumab deruxtecan), Breakthrough Therapy Designation (BTD) in the […]